Panobinostat Recaptured Response in Bortezomib-Refractory Myeloma Patients
The addition of the oral pan-deacetylase inhibitor panobinostat to bortezomib helped to elicit responses in about one-third of heavily pre-treated patients with multiple myeloma who were refractory of bortezomib, according to the phase II results of the PANORAMA 2 study. (Source: Cancer Network)
Source: Cancer Network - September 30, 2013 Category: Cancer & Oncology Source Type: news
European Commission approves VELCADE®
Janssen-Cilag International NV (Janssen) has announced that the European Commission (EC) has approved the use of VELCADE® (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone (VD) or thalidomide and dexamethasone (VTD).
You must sign in to continue reading this articleread more (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 15, 2013 Category: Drugs & Pharmacology Authors: mz_loader Tags: Transplantation Latest News Source Type: news
European Commission approves VELCADE®
Janssen-Cilag International NV (Janssen) has announced that the European Commission (EC) has approved the use of VELCADE® (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone (VD) or thalidomide and dexamethasone (VTD). (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 14, 2013 Category: Drugs & Pharmacology Source Type: news
Pomalidomide Celgene® - (pomalidomide) licensed for use in the UK for the treatment of adults with relapsed/refractory multiple myeloma
Celgene has confirmed that Pomalidomide Celgene® - (pomalidomide), a new oral blood cancer therapy, has been granted Marketing Authorisation by the European Medicines Agency and is now available in the UK and Ireland. Pomalidomide is for use in combination with dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma (rrMM) who have received at least two prior therapies including both lenalidomide and bortezomib, and have demonstrated disease progression while on their last therapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 12, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
European Commission Approves VELCADE(R) as a Frontline Induction Therapy before Stem Cell Transplantation
Decision could significantly improve transplant outcomes for patients with multiple myeloma
BEERSE, Belgium--(Healthcare Sales & Marketing Network)--Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved ... Biopharmaceuticals, Oncology, RegulatoryJanssen, VELCADE, bortezomib, induction therapy, multiple myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 8, 2013 Category: Pharmaceuticals Source Type: news
Updated Understanding Pomalyst® (pomalidomide) Capsules Series now available on the web
The U.S. Food and Drug Administration (FDA) approved Pomalyst® (pomalidomide) on February 8, 2013, to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
The National Comprehensive Cancer Network (NCNN) has included pomalidomide plus dexamethasone as a salvage therapy option in patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy. For steroid-intolerant individuals, the NCNN Multiple Myeloma Panel suggests considering pomali...
Source: International Myeloma Foundation - August 5, 2013 Category: Hematology Source Type: news
EU Says Yes to Subcutaneous Herceptin and Other ExtensionsEU Says Yes to Subcutaneous Herceptin and Other Extensions
A positive opinion in Europe has been issued for a subcutaneous formulation of trastuzumab, plus expanded indications for lapatinib and bortezomib. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology Obituary Source Type: news
US FDA approves REVLIMID
Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for REVLIMID® (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 6, 2013 Category: Drugs & Pharmacology Source Type: news
Novel Agents Now Prevalent Method of Care for Multiple Myeloma
A majority of patients with multiple myeloma are being treated with novel agents such as thalidomide, bortezomib, and lenalidomide within a year of diagnosis instead of the chemotherapeutic regimens that were more prevalent a decade ago, according to a new study. (Source: Cancer Network)
Source: Cancer Network - May 2, 2013 Category: Cancer & Oncology Source Type: news
Promising New Compound For Battling Kidney Cancer
Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer. Named TIR-199, the compound targets the "proteasome," a cellular complex in kidney cancer cells, similar to the way the drug bortezomib, approved by the Food and Drug Administration, targets and inhibits the proteasome in multiple myeloma cells, a cancer coming from bone marrow... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2013 Category: Consumer Health News Tags: Urology / Nephrology Source Type: news
New compound holds high promise in battling kidney cancer
(University of California - Riverside) Chemists at the University of California, Riverside, have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer. Named TIR-199, the compound targets the "proteasome," a cellular complex in kidney cancer cells, similar to the way the drug bortezomib, approved by the Food and Drug Administration, targets the proteasome in multiple myeloma cells, a cancer coming from bone marrow. The development of TIR-199 was announced Feb. 19, 2013, in Dubai. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2013 Category: Global & Universal Source Type: news
LCNDG Rapid Review: Lenalidomide for 1st relapse multiple myeloma after bortezomib
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
NICE recommends the use of lenalidomide for relapsed multiple myeloma only in those who have received two or more prior therapies.
The best available evidence to support the use of lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma comes from two phase III studies (MM-009 and MM-010). Both trials compared lenalidomide/dexamethasone to dexamethasone alone, and both trials used a primary endpoint of time to disease progression. There was only a limited number of patients in the two phase III ...
Source: NeLM - Drug Specific Reviews - February 15, 2013 Category: Drugs & Pharmacology Source Type: news
FDA Approves Pomalidomide for Advanced Multiple Myeloma
Pomalidomide has been approved for the treatment of patients with multiple myeloma whose disease has progressed after treatment with at least two prior therapies, including lenalidomide and bortezomib,... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - February 12, 2013 Category: Cancer & Oncology Source Type: news
LCNDG Rapid Review: Bortezomib for first-line, transplant unsuitable multiple myeloma
Source: London Cancer New Drugs Group
Area: Evidence > Drug Specific Reviews
There are no trials directly comparing bortezomib, melphalan, and prednisolone versus thalidomide-based regimens in patients with multiple myeloma who are not able to receive high-dose therapy and stem cell transplant.
The phase III open-label randomised control trial investigating melphalan-prednisolone (control arm) against bortezomib-melphalan-prednisolone (bortezomib arm) reported a median time to progression of 24 months in the bortezomib arm and 16.6 months in the control arm (hazard ratio 0.48; P<0.001). The response cou...
Source: NeLM - Drug Specific Reviews - February 12, 2013 Category: Drugs & Pharmacology Source Type: news
Pomalyst (pomalidomide) For Advanced Multiple Myeloma Approved By FDA
Pomalyst (pomalidomide) has been approved by the FDA for the treatment of patients with multiple myeloma whose cancer progressed after being treated with other medications. Pomalyst, which is presented in capsule form, modulates the immune system so that the patient's own body destroys cancerous cells and undermines their growth. Pomalidomide is aimed at multiple myeloma patients who had been administered at least two previous therapies which did not stop the progression of the disease within two months (relapsed and refractory), including therapies with bortezomib and lenalidomide... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 11, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
